ICS withdrawal and exacerbation risk by GOLD 2017 Report: post hoc analysis of the WISDOM trial

Introduction: The 2017 GOLD* A–D grouping scheme is solely based on exacerbation history and symptoms, and no longer considers lung function. Aim: To examine the effect of ICS withdrawal in the WISDOM trial within the new GOLD 2017 groups A–D. Methods: In WISDOM, a 12-month, double-blind, parallel-group study, patients with COPD who had ≥1 exacerbation in the preceding 12 months and FEV₁ <50% predicted (GOLD...